(VIANEWS) – AMSC (AMSC.OL), SCATEC (SCATC.OL), SHELL PLC (SHELL.AS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, invests in maritime assets and companies in the United States. It operates one international subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was incorporated in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr-1.74.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 75.8% and 46.8%, respectively.
More news about AMSC.
2. SCATEC (SCATC.OL)
111% sales growth and 11.65% return on equity
Scatec ASA, together with its subsidiaries, provides renewable energy solutions worldwide. The company operates through Power Production; Services; and Development & Construction segments. It produces and sells solar, winds, and hydro generated electricity. The company also develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. The company is also involved in the engineering, procurement, and construction, as well as operation, maintenance, and asset management of power plants. It has a total of 4.2 GW in operation and under construction. The company was formerly known as Scatec Solar ASA and changed its name to Scatec ASA in November 2020. Scatec ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, SCATEC has a trailing twelve months EPS of kr4.24.
PE Ratio
SCATEC has a trailing twelve months price to earnings ratio of 18.5. Meaning, the purchaser of the share is investing kr18.5 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.65%.
Sales Growth
SCATEC’s sales growth is negative 0.8% for the current quarter and 111% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 36.8% and positive 528.6% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 19, 2023, the estimated forward annual dividend rate is 1.94 and the estimated forward annual dividend yield is 2.78%.
Yearly Top and Bottom Value
SCATEC’s stock is valued at kr78.45 at 07:20 EST, below its 52-week high of kr85.50 and way above its 52-week low of kr52.50.
More news about SCATEC.
3. SHELL PLC (SHELL.AS)
14.6% sales growth and 10.31% return on equity
Shell plc operates as an energy and petrochemical company Europe, Asia, Oceania, Africa, the United States, and Rest of the Americas. The company operates through Integrated Gas, Upstream, Marketing, Chemicals and Products, and Renewables and Energy Solutions segments. It explores for and extracts crude oil, natural gas, and natural gas liquids; markets and transports oil and gas; produces gas-to-liquids fuels and other products; and operates upstream and midstream infrastructure to deliver gas to market. The company also markets and trades natural gas, liquefied natural gas (LNG), crude oil, electricity, carbon-emission rights; and markets and sells LNG as a fuel for heavy-duty vehicles. In addition, it trades in and refines crude oil and other feed stocks, such as low-carbon fuels, lubricants, bitumen, sulphur, gasoline, diesel, aviation fuel, and marine fuel; produces and sells petrochemicals for industrial use; and manages oil sands activities. Further, the company produces base chemicals comprising ethylene, propylene, and aromatics, as well as intermediate chemicals, such as styrene monomer, propylene oxide, solvents, detergent alcohols, ethylene oxide, and ethylene glycol. Additionally, it generates electricity through wind and solar resources; produces and sells hydrogen; and provides electric vehicle charging services. The company was formerly known as Royal Dutch Shell plc and changed its name to Shell plc in January 2022. Shell plc was founded in 1907 and is headquartered in London, the United Kingdom.
Earnings Per Share
As for profitability, SHELL PLC has a trailing twelve months EPS of €2.53.
PE Ratio
SHELL PLC has a trailing twelve months price to earnings ratio of 13.58. Meaning, the purchaser of the share is investing €13.58 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.31%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 15, 2024, the estimated forward annual dividend rate is 1.27 and the estimated forward annual dividend yield is 3.72%.
Moving Average
SHELL PLC’s worth is way above its 50-day moving average of €31.23 and way higher than its 200-day moving average of €30.06.
Sales Growth
SHELL PLC’s sales growth is negative 5.4% for the ongoing quarter and 14.6% for the next.
More news about SHELL PLC.
4. SARTORIUS STED BIO (DIM.PA)
12.2% sales growth and 8.15% return on equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Moving Average
SARTORIUS STED BIO’s value is higher than its 50-day moving average of €244.13 and way higher than its 200-day moving average of €232.42.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 10.9% and positive 44.7% for the next.
Volume
Today’s last reported volume for SARTORIUS STED BIO is 48852 which is 29.49% below its average volume of 69287.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 2.72B for the twelve trailing months.
More news about SARTORIUS STED BIO.
5. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through seven segments: Fishmeal, Fish Oil and Fish Feed; Freshwater FO; Freshwater SCT; Farming FO; Farming SCT; Services; and Sales & Other. The company's products include fresh and frozen whole salmon, fresh and frozen salmon fillets, fresh skin-packed salmon portions, frozen salmon portions and tails, frozen smoked salmon and salmon fillets, frozen salmon bits and pieces, frozen salmon off-cuts and belly flaps, frozen salmon heads, salmon backbones, and salmon skin under the Bakkafrost, 18 ISLANDS, HEIMLAND, BAKKA SALMON, NATIVE HEBRIDEAN, and LOCHLANDER brands. It is also involved in the production and sale of fishmeal, fish oil, and fish feed; production of eggs from breeding self-owned salmon strains; production of smolts; and on-growing of salmon. In addition, the company manages a fleet of farming service vessels; provides fish transportation, treatments, net cleaning, harvesting, freight ans logistical, and heavy marine support services; converts organic waste into biogas, heating, electricity, and fertilizers; produces styrofoam boxes; and optimizes the value creation and retention from the harvested fish. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr23.61.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 26.24. Meaning, the purchaser of the share is investing kr26.24 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
Sales Growth
BAKKAFROST’s sales growth is 7.1% for the present quarter and 11.7% for the next.
More news about BAKKAFROST.
6. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 19.84% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing kr17.8 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
More news about VISTIN PHARMA.
